A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ.
Ahn DH, et al. Among authors: deleon t.
Invest New Drugs. 2022 Feb;40(1):134-141. doi: 10.1007/s10637-021-01170-x. Epub 2021 Aug 31.
Invest New Drugs. 2022.
PMID: 34463891
Clinical Trial.